NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全身性硬皮症伴隨的間質性肺部疾病(SSc-ILD)- 流行病學預測 2028年

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 915404
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 2-10個工作天內
價格
全身性硬皮症伴隨的間質性肺部疾病(SSc-ILD)- 流行病學預測 2028年 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Epidemiology Forecast to 2028
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的全身性硬皮症伴隨的間質性肺部疾病(SSc-ILD)的2017年的患病數估算為7萬1,375人。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的全身性硬皮症伴隨的間質性肺部疾病(SSc-ILD)市場調查,疾病概要,流行病學的預測,各國患病數的變化與預測等資料彙整。

目錄

第1章 重要洞察

第2章 疾病背景和概要:全身性硬皮症伴隨的間質性肺部疾病(SSc-ILD)

  • 簡介
  • 原因
  • 危險因素
  • 徵兆與症狀
  • 病理生理學
  • 診斷方法
    • 診斷演算法
    • 疾病管理
    • 生物標記

第3章 治療貢獻的組織

第4章 關鍵意見領袖的意見

第5章 流行病學和患者人口

  • 主要調查結果

第6章 主要7個國家的全身性硬皮症伴隨的間質性肺部疾病(SSc-ILD)的患病數

第7章 全身性硬皮症伴隨的間質性肺部疾病(SSc-ILD)的流行病學:各國

  • 美國
    • 假設和理論的根據
    • SSc-ILD的總患病數
    • SSc-ILD的患病數:性別
    • SSc-ILD的診斷數
    • SSc-ILD的治療可能病例數
  • 歐盟5國
    • 德國
      • 假設和理論的根據
      • SSc-ILD的總患病數
      • SSc-ILD的患病數:性別
      • SSc-ILD的診斷數
      • SSc-ILD的治療可能病例數
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 假設和理論的根據
    • SSc-ILD的總患病數
    • SSc-ILD的患病數:性別
    • SSc-ILD的診斷數
    • SSc-ILD的治療可能病例數

第8章 病例報告

第9章 附錄

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI0394

DelveInsight's "Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Epidemiology Forecast to 2028" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of SSc-ILD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Epidemiology

The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology division provides the insights about historical and current patient pool and forecasted trend for all seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the total disease prevalence, diagnosed cases, treatable cases and gender specific prevalent population in the US, EU5 and Japan.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, total diagnosed cases and total treatable cases) scenario of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, total prevalent population of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) in seven major markets was found to be 71,375 in 2017. 

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Report Insights

  • The report covers detailed overview of SSc-ILD explaining its causes, symptoms, pathophysiology, diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, and UK) and Japan.
  • The Report highlights the unmet needs of SSc-ILD.
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by total prevalent population, diagnosed cases, treatable cases and gender specific prevalent population in 7MM.

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Prevalent cases
  • Diagnosed cases
  • Treatable cases
  • Gender specific prevalent population

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Report Assessment

  • Patient Segmentation
  • Disease Risk & Burden
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Systemic Sclerosis-associated Interstitial Lung Disease: Disease Background and Overview

  • 2.1. Introduction
  • 2.2. Causes
  • 2.3. Risk Factors
  • 2.4. Signs and Symptoms
  • 2.5. Pathophysiology
  • 2.6. Diagnostic Approach
    • 2.6.1. Diagnostic algorithm for Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
    • 2.6.2. Management of Systemic Sclerosis-associated Interstitial Lung Disease
    • 2.6.3. Biomarkers in Systemic Sclerosis-associated Interstitial Lung Disease

3. Organizations contributing toward SSc-ILD

4. KOL's Views: Systemic Sclerosis-associated Interstitial Lung Disease

5. Epidemiology and Patient Population

  • 5.1. Key Findings

6. 7MM Total Prevalent Patient Population of Systemic Sclerosis-associated Interstitial Lung Disease

7. Country Wise-Epidemiology of SSc-ILD

  • 7.1. United States
    • 7.1.1. Assumptions and Rationale
    • 7.1.2. Total Prevalent Population of SSc-ILD
    • 7.1.3. Total Gender Specific Prevalent Population of SSc-ILD
    • 7.1.4. Total Diagnosed Cases of SSc-ILD
    • 7.1.5. Total Treatable Cases of SSc-ILD
  • 7.2. Europe
    • 7.2.1. Assumptions and Rationale
  • 7.3. Germany
    • 7.3.1. Total Prevalent Population of SSc-ILD
    • 7.3.2. Total Gender Specific Prevalent Population of SSc-ILD
    • 7.3.3. Total Diagnosed Cases of SSc-ILD
    • 7.3.4. Total Treatable Cases of SSc-ILD
  • 7.4. France
    • 7.4.1. Total Prevalent Population of SSc-ILD
    • 7.4.2. Total Gender Specific Prevalent Population of SSc-ILD
    • 7.4.3. Total Diagnosed Cases of SSc-ILD
    • 7.4.4. Total Treatable Cases of SSc-ILD
  • 7.5. Italy
    • 7.5.1. Total Prevalent Population of SSc-ILD
    • 7.5.2. Total Gender Specific Prevalent Population of SSc-ILD
    • 7.5.3. Total Diagnosed Cases of SSc-ILD
    • 7.5.4. Total Treatable Cases of SSc-ILD
  • 7.6. Spain
    • 7.6.1. Total Prevalent Population of SSc-ILD
    • 7.6.2. Total Gender Specific Prevalent Population of SSc-ILD
    • 7.6.3. Total Diagnosed Cases of SSc-ILD
    • 7.6.4. Total Treatable Cases of SSc-ILD
  • 7.7. The United Kingdom
    • 7.7.1. Total Prevalent Population of SSc-ILD
    • 7.7.2. Total Gender Specific Prevalent Population of SSc-ILD
    • 7.7.3. Total Diagnosed Cases of SSc-ILD
    • 7.7.4. Total Treatable Cases of SSc-ILD
  • 7.8. Japan
    • 7.8.1. Assumptions and Rationale
    • 7.8.2. Total Prevalent Population of SSc-ILD
    • 7.8.3. Total Gender Specific Prevalent Population of SSc-ILD
    • 7.8.4. Total Diagnosed Cases of SSc-ILD
    • 7.8.5. Total Treatable Cases of SSc-ILD

8. Case Reports

  • 8.1. Scleroderma-related interstitial lung disease: reporting four cases of SSc-ILD in the US
  • 8.2. Systemic scleroderma-related interstitial pneumonia associated with borderline pulmonary arterial hypertension - Case report of a Japanese woman
  • 8.3. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease

9. Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

  • Table 1 Quantitative and semi-quantitative scoring for SSc-ILD through HRCT: Wells et al.
  • Table 2 High-resolution computed tomography advantages and drawbacks
  • Table 3 Main biomarkers associated with SSc-ILD
  • Table 4 Main biomarkers associated with SSc-ILD
  • Table 5 Organizations contributing toward SSc-ILD
  • Table 6 Total Prevalent Population of SSc-ILD in the 7MM (2017-2028)
  • Table 7 Total Prevalent Population of SSc-ILD in the US (2017-2028)
  • Table 8 Gender specific prevalent population of SSc-ILD in the US (2017-2028)
  • Table 9 Diagnosed cases of SSc-ILD in the US (2017-2028)
  • Table 10 Treatable cases of SSc-ILD in the US (2017-2028)
  • Table 11 Total Prevalent Population of SSc-ILD in Germany (2017-2028)
  • Table 12 Gender specific prevalent population of SSc-ILD in Germany (2017-2028)
  • Table 13 Diagnosed cases of SSc-ILD in Germany (2017-2028)
  • Table 14 Treatable cases of SSc-ILD in Germany (2017-2028)
  • Table 15 Total Prevalent Population of SSc-ILD in France (2017-2028)
  • Table 16 Gender specific prevalent population of SSc-ILD in France (2017-2028)
  • Table 17 Diagnosed cases of SSc-ILD in France (2017-2028)
  • Table 18 Treatable cases of SSc-ILD in France (2017-2028)
  • Table 19 Total Prevalent Population of SSc-ILD in Italy (2017-2028)
  • Table 20 Gender specific prevalent population of SSc-ILD in Italy (2017-2028)
  • Table 21 Diagnosed cases of SSc-ILD in Italy (2017-2028)
  • Table 22 Treatable cases of SSc-ILD in Italy (2017-2028)
  • Table 23 Total Prevalent Population of SSc-ILD in Spain (2017-2028)
  • Table 24 Gender specific prevalent population of SSc-ILD in Spain (2017-2028)
  • Table 25 Diagnosed cases of SSc-ILD in Spain (2017-2028)
  • Table 26 Treatable cases of SSc-ILD in Spain (2017-2028)
  • Table 27 Total Prevalent Population of SSc-ILD in the UK (2017-2028)
  • Table 28 Gender specific prevalent population of SSc-ILD in the UK (2017-2028)
  • Table 29 Diagnosed cases of SSc-ILD in the UK (2017-2028)
  • Table 30 Treatable cases of SSc-ILD in the UK (2017-2028)
  • Table 31 Total Prevalent Population of SSc-ILD in Japan (2017-2028)
  • Table 32 Gender specific prevalent population of SSc-ILD in Japan (2017-2028)
  • Table 33 Diagnosed cases of SSc-ILD in Japan (2017-2028)
  • Table 34 Treatable cases of SSc-ILD in Japan (2017-2028)

List of Figures

  • Figure 1 Total Prevalent Population of SSc-ILD in the 7 MM (2017)
  • Figure 2 Total Prevalent Population of SSc-ILD in the 7 MM (2028)
  • Figure 3 Causes of SSc-ILD
  • Figure 4 Histological sections of normal lung tissue and lung tissue with ILD
  • Figure 5 Risk Factors of SSc- ILD
  • Figure 6 Symptoms associated with SSc-ILD
  • Figure 7 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
  • Figure 8 Diagnostic algorithm for SSc-ILD
  • Figure 9 Management of SSc-ILD
  • Figure 10 Total Prevalent Patient Population of SSc-ILD in the 7MM (2017-2028)
  • Figure 11 Total Prevalent Population of SSc-ILD in the US (2017-2028)
  • Figure 12 Gender specific prevalent population of SSc-ILD in the US (2017-2028)
  • Figure 13 Diagnosed cases of SSc-ILD in the US (2017-2028)
  • Figure 14 Treatable cases of SSc-ILD in the US (2017-2028)
  • Figure 15 Total Prevalent Population of SSc-ILD in Germany (2017-2028)
  • Figure 16 Gender specific prevalent population of SSc-ILD in Germany (2017-2028)
  • Figure 17 Diagnosed cases of SSc-ILD in Germany (2017-2028)
  • Figure 18 Treatable cases of SSc-ILD in Germany (2017-2028)
  • Figure 19 Total Prevalent Population of SSc-ILD in France (2017-2028)
  • Figure 20 Gender specific prevalent population of SSc-ILD in France (2017-2028)
  • Figure 21 Diagnosed cases of SSc-ILD in France (2017-2028)
  • Figure 22 Treatable cases of SSc-ILD in France (2017-2028)
  • Figure 23 Total Prevalent Population of SSc-ILD in Italy (2017-2028)
  • Figure 24 Gender specific prevalent population of SSc-ILD in Italy (2017-2028)
  • Figure 25 Diagnosed cases of SSc-ILD in Italy (2017-2028)
  • Figure 26 Treatable cases of SSc-ILD in Italy (2017-2028)
  • Figure 27 Total Prevalent Population of SSc-ILD in Spain (2017-2028)
  • Figure 28 Gender specific prevalent population of SSc-ILD in Spain (2017-2028)
  • Figure 29 Diagnosed cases of SSc-ILD in Spain (2017-2028)
  • Figure 30 Treatable cases of SSc-ILD in Spain (2017-2028)
  • Figure 31 Total Prevalent Population of SSc-ILD in the UK (2017-2028)
  • Figure 32 Gender specific prevalent population of SSc-ILD in the UK (2017-2028)
  • Figure 33 Diagnosed cases of SSc-ILD in the UK (2017-2028)
  • Figure 34 Treatable cases of SSc-ILD in the UK (2017-2028)
  • Figure 35 Total Prevalent Population of SSc-ILD in Japan (2017-2028)
  • Figure 36 Gender specific prevalent population of SSc-ILD in Japan (2017-2028)
  • Figure 37 Diagnosed cases of SSc-ILD in Japan (2017-2028)
  • Figure 38 Treatable cases of SSc-ILD in Japan (2017-2028)